9/29/2020 7:24:19 AM
Concert Expects CTP-692 Phase 2 Topline Results In Q1 Of 2021; Completes Enrollment
9/23/2019 7:04:59 AM
Concert Pharma Names Jeffrey Munsie As Chief Legal Officer
9/17/2019 7:02:56 AM
Concert Pharma Completes Enrollment In Second Open Label Trial Of CTP-543
9/12/2019 7:09:08 AM
Concert Pharma Says CTP-543 Phase 2 Alopecia Areata Data Selected For Late-Breaker Oral Presentation At EADV Congress
6/12/2019 7:06:07 AM
Concert Pharma Reports Positive Results From Phase 1 Studies Of CTP-692 In Healthy Volunteers
5/16/2019 7:10:42 AM
Concert Pharma Begins New Open Label Trial To Evaluate Once-Daily Vs. Twice-Daily Dosing Of CTP-543
4/29/2019 7:15:38 AM
Concert Pharma Names Jesper Høiland To Board
4/10/2019 6:36:42 AM
Concert Pharma Initiates Phase 1 Multiple-Ascending Dose Trial Of CTP-692 As An Adjunctive Treatment For Schizophrenia
3/6/2019 7:19:53 AM
Concert Pharma Begins Open Label Trial To Evaluate Once-Daily Vs. Twice-Daily Dosing Of CTP-543
3/1/2019 7:03:26 AM
Concert Pharma Presents Interim CTP-543 Phase 2 Data In Alopecia Areata At AAD Annual Meeting
1/24/2019 7:07:36 AM
Concert Begins Phase 1 Single-Ascending Dose Trial Of CTP-692 As An Adjunctive Treatment For Schizophrenia
1/22/2019 7:04:55 AM
Concert Pharma Completes Enrollment Of 12 Mg Cohort In Phase 2a Trial Of CTP-543 In Alopecia Areata
12/17/2018 7:04:19 AM
Concert Pharma Begins Phase 1 Program Of CTP-692 For Treatment Of Schizophrenia
11/1/2018 7:16:51 AM
Concert Pharma Q3 Net Loss $17.4 Mln Or $0.74/shr Vs. Net Income $128.1 Mln Or $5.61/shr Last Year
8/2/2018 7:15:19 AM
Concert Pharmaceuticals Q2 Loss/shr Narrows To $0.57 From $0.58 Last Year
5/3/2018 7:12:58 AM
Concert Pharmaceuticals Q1 Net Loss $4.5 Mln Or $0.19/shr Vs. Net Loss $13.3 Mln Or $0.60/shr Last Year